P1, N=18, Not yet recruiting, Baylor College of Medicine | Trial completion date: Jun 2038 --> Jun 2040 | Trial primary completion date: Jun 2023 --> Jun 2025
over 1 year ago
Trial completion date • Trial primary completion date • Virus specific T cells
Humanized CD30.CARs combined with the 4-1BB-derived spacer did not exhibit any nonspecific interactions with CD16+ immune cells, while displaying superior efficacy in vitro , better persistence in vivo in various humanized mouse models, and more importantly an improved safety profile in a leukemia model with high tumor burden. Conclusions Our re-engineered CD30.CAR construct, consisting of a humanized CD30.CAR and a 4-1BB-derived spacer, is likely to improve allogeneic CD30.CAR EBVST performance.